DNA enzyme’s speed confirms physics law – Futurity: Research News
By Dr. Matthew Watson
DNA enzyme's speed confirms physics law Futurity: Research News “Ever since the original experiments, we've noticed RecBCD molecules have quite a broad range of speeds,” says Kowalczykowski, a member of the department of microbiology and molecular genetics and the UC Davis Cancer Center. Liu used the ... |
Uncategorized
Comments Off on DNA enzyme’s speed confirms physics law – Futurity: Research News |
July 21st, 2013
Doctors apply lessons from boy’s case in sequencing genes of 25 other patients – Milwaukee Journal Sentinel
By Dr. Matthew Watson
Doctors apply lessons from boy's case in sequencing genes of 25 other patients Milwaukee Journal Sentinel Writing with two dozen colleagues, Howard Jacob, head of human and molecular genetics at the Medical College of Wisconsin, says the use of sequencing in hospitals "may still be debated, but we challenge the fence sitters to do 20 cases of their own and ... |
Uncategorized
Comments Off on Doctors apply lessons from boy’s case in sequencing genes of 25 other patients – Milwaukee Journal Sentinel |
July 21st, 2013
“Molecular Postal System” Used in Quest to Develop Low-Cost Sterilization … – HealthCanal.com
By Dr. Matthew Watson
“Molecular Postal System” Used in Quest to Develop Low-Cost Sterilization ... HealthCanal.com WINSTON-SALEM, N.C. - As an expert in molecular genetics, Colin E. Bishop, Ph.D.'s, usual role at the Wake Forest Baptist Medical Center's Institute for Regenerative Medicine is to apply the techniques of genetics and developmental biology to the ... |
Uncategorized
Comments Off on “Molecular Postal System” Used in Quest to Develop Low-Cost Sterilization … – HealthCanal.com |
July 21st, 2013
CAMH scientists discover genetic changes that may contribute to the onset of … – Placentia Charter
By Dr. Matthew Watson
 Placentia Charter | CAMH scientists discover genetic changes that may contribute to the onset of ... Placentia Charter The study is published in the current issue of Human Molecular Genetics, and was funded by the Canadian Institutes of Health Research (CIHR). In the first study of its kind, scientists at CAMH and The Centre for Applied Genomics (TCAG) at The Hospital ... |
Uncategorized
Comments Off on CAMH scientists discover genetic changes that may contribute to the onset of … – Placentia Charter |
July 21st, 2013
Treat an upset tummy with curd – Times of India
By Dr. Matthew Watson
Treat an upset tummy with curd Times of India Manuela Raffatellu, assistant professor of microbiology and molecular genetics, and colleagues at UC Irvine and the University of Washington identified how a probiotic strain of E. coli reduces salmonella colonization by competing with this pathogen ... |
Uncategorized
Comments Off on Treat an upset tummy with curd – Times of India |
July 21st, 2013
Applause for business achievements – Lima Ohio
By Dr. Matthew Watson
Applause for business achievements Lima Ohio He is a 1995 graduate of The Ohio State University with a bachelor's degree in science in molecular genetics. He then attended Kirksville College of Osteopathic Medicine in Kirksville, Mo., where he received his Doctorate of Osteopathic Medicine. In ... |
Uncategorized
Comments Off on Applause for business achievements – Lima Ohio |
July 21st, 2013
California Stem Cell Agency to Commit 20 Percent of Remaining Cash
By Dr. Matthew Watson
Thursday is expected to move forward with plans to give away $128
million, roughly 20 percent of its remaining funds.
of the $3 billion agency's hallmark efforts. The other “concept”
rounds up next week include a $35 million “tools and technology”RFA and $23 million to recruit four more star, stem cell scientists to California.
billion of its $3 billion so far with about $700 million available
for future spending. The remainder is going for the agency's
administrative expenses. Cash for new grants is expected to run out
sometime in 2017. Total cost of the agency's efforts run to about $6
billion because it operates with money borrowed by the state and must
pay interest.
developing a plan to develop new sources of funding with an eye on
some sort of public-private model. It solicited proposals in May for
help with the effort, with the goal of completing a plan by this
fall. At last report, however, the contract with the consultant had
not been let.
called, is likely to come up at next week's governing board meeting
along with a review of agency goals for the 2013-14 fiscal year.
also be heard by the agency's standards group next Wednesday.
implementing recommendations from a performance audit in May 2012.
The audit said the agency was laboring under a range of problems that
include protection of its intellectual property and management of its
nearly 500 grants plus an inadequate ability to track its own
performance. A staff Power Point presentation seems to indicate that it is making substantial progress in solving the problems identified by the audit.
Burlingame near the San Francisco Airport. Two remote locations where
the public can participate are also available in Los Angeles.
Addresses can be found on the agenda.
provide live coverage of the meeting based on the Internet audiocast
with stories filed as warranted.
Source:Stem Cell Therapy
Comments Off on California Stem Cell Agency to Commit 20 Percent of Remaining Cash |
July 21st, 2013
Paying for Human Eggs, Ivan Illich and Jerry Brown
By Dr. Matthew Watson
stalled in a technical parliamentary process as opponents continue to
wage their campaign urging Gov. Jerry Brown to veto the proposal,
which swept easily through the legislature.
industry-sponsored measure appeared this week as an op-ed in The Sacramento Bee. The legislation would allow women to be paid for eggs for scientific research. The op-ed piece invoked the philosopher Ivan Illich, a
longtime friend of Jerry Brown and much respected by him.
Scheper-Hughes of the Center for Genetics and Society of Berkeley,
the July 16 article said,
“The late historian of science and
technology, Ivan Illich, warned against the processes of medical
industries which 'create new needs and control their satisfaction and
turn human beings and their creativity into objects.'"
“Women's research eggs (have) become
the hot new bio-product, increasing the profits of the
multibillion-dollar-per-year infertility industry at the expense of
women's health, safety and possibly, their future fertility. Is this
the 'equity' we want for ourselves, our sisters and our daughters?”
Illich, whom he first met in 1976. Brown said that Illich
“...bore witness to the destructive
power of modern institutions that 'create needs faster than they can
create satisfaction, and in the process of trying to meet the needs
they generate, they consume the earth.'”
Assemblywoman Susan Bonilla, D-Concord) would remove a ban in
California on paying women who provide their eggs for scientific
research. Currently women who provide eggs for fertility purposes can
be paid, sometimes as much as $50,000, depending on the
characteristics of the woman providing the eggs. The bill would not
alter the ban on using research funds from the California stem cell
agency to pay for eggs. However, the agency next week will consider a proposal to allow use of agency funds to purchase stem cell lines
derived from eggs through compensation. (For
more information on
the bill,
see here, here and here.)
approval on July 1. The governor has 12 days to act on the measure
once it actually reaches his desk. However, as of this morning, the
legislation remained in what is known as the “engrossing and
enrolling” process. It could be a routine delay but the process can
also be used to manage the flow of legislation to the governor. Brown
is currently on a two-week trip to Germany and Ireland and is not
expected to return until near the first of August.
Source:Stem Cell Therapy
Comments Off on Paying for Human Eggs, Ivan Illich and Jerry Brown |
July 21st, 2013
California’s $70 Million ‘Alpha’ Stem Cell Clinic Plan Headed for Approval Next Week
By Dr. Matthew Watson
 |
| Alpha clinic organizational diagram Graphic by CIRM |
is likely to approve a $70 million plan to build a taxpayer-financed
chain of “Alpha” stem cell clinics in what could be a major step
towards making California the stem cell capital of the world,
at existing institutions or businesses to be funded at up to $11
million each over five years. Also proposed is a coordination and
information center that would receive $15 million over five years.
the Alpha clinics would be the first-ever “clinical trials network focused around a broad therapeutic platform.”
cell projects from the around the world as well as those
funded by the $3 billion California stem cell agency. The proposal
would be one of the largest single research efforts funded by the
agency, formally known as the California Institute for Regenerative
Medicine (CIRM) and use about 10 percent of its remaining cash.
of a sturdy foundation for the stem cell industry in California,
capitalizing on the burgeoning, international lure of stem cell
treatments. Indeed, one of the objectives of the information center
is to divert people from dubious treatments elsewhere.
in quality information about stem cell treatments, according to a CIRM document, which said,
“By providing this resource, the public and potential patients
would be better educated and informed, whether or not they should opt
to enroll in clinical trials or approved treatments at any of the
Alpha clinics.”
CIRM President Alan Trounson, a pioneer in IVF research and the IVF
business. His proposal has received early and heavy
attention on the CIRM website with a video, blog items and a white paper.
attention although a researcher from an institution that could be a
candidate for an Alpha clinic commented harshly in May on the California
Stem Cell Report, calling the proposal “an irresponsible waste”and a “boondoggle for some medical schools.” The researcher, who
asked that he/she not be identified, said,
“CIRM will pay for an unneeded
infrastructure that will be empty space and staff sitting on their
hands 99 percent of the time. Or worse yet, CIRM will pay but
the space will be used for other things, other clinic procedures paid
for by insurance.”
Medicine quoted Mahendra Rao, director of the Center for Regenerative
Medicine at the US National Institutes of Health (NIH), as applauding the concept. However, Rao said he doesn't
anticipate the approach being tried nationally soon.
“Rao regularly asks researchers
hoping to advance promising stem cell therapies whether they require
additional clinical infrastructure. 'So far, what they've told us is
they'll let us know if they need anything more than (the) programs
that we have already established,' he says.”
for Alpha clinics is not addressed in the CIRM concept plan. Also
absent is much discussion of the business aspects of the proposal. It
does mention “corporate sponsors” in passing. In a CIRM blog item
yesterday, Natalie DeWitt, special project director at the agency,
touched on business elements, declaring,
“(The proprosal) will yield better
clinical trial design, accelerated approval of high quality
treatments, and data and know-how to inform regulatory and
reimbursement decisions.”
for creating ways to generate profits for stem cell firms.
to bring substantial support from their own institutions and
“demonstrate the potential to bring in a pipeline of additional
stem cell-based therapeutic trials as well as future funding streams
to sustain the clinic.” Applicants would also be “evaluated in
their ability to create a positive 'brand' that would attract
clinical trials.”
reviewers, all of whom come from out-of-state, would have special
expertise to evaluate the business aspects of each applicant's
proposal along with their business track record.
25 at their meeting in Burlingame, Ca., is a request for approval of the concept, which
would be fleshed out for the RFA. The governing board almost always
approves staff concepts, although they may modify them slightly. A
number of directors come from institutions that are likely to be
applicants in the program. They can participate in voting on the
concept plan but would be barred from voting on any applications that
come in later. The two RFAs could go out as early as October with
approval of funding of applications one year from now.
site, members of the public can participate from two teleconference
locations in the Los Angeles area. The specific locations can be
found on the meeting agenda.
provide live coverage of the entire meeting, filing reports as
warranted based on the Internet audiocast.
document on the plan.
“To accelerate therapeutic
development and delivery of stem cell therapies, CIRM proposes
establishing the CIRM Alpha Stem Cell Clinics Network (CASC Network).
The network will be designed to support projects emanating from
CIRM’s funding pipeline, as well as scientifically outstanding stem
cell products being developed worldwide and brought to California.
Conceptually, the CASC Network is intended to be a sustainable
infrastructure designed to support academic- and industry-initiated
clinical trials, and delivery of therapies proven safe and
effective.”“The major thrusts (of the overall
plan) will be:
• Development of clinical capacity
and associated resources designed to support the effective
implementation and execution of clinical trials and delivery of
registered stem cell therapies
• Compilation of data and
information concerning clinical trial experience and therapy outcomes
to further inform the research, regulatory, and general community
about the status of investigational stem cell interventions and
long-term outcomes
• Dissemination of information to
the public and counseling of patients and potential trial subjects
about therapeutic options and clinical trials involving stem cells in
the network and elsewhere.”
“The long-term vision is for the
Alpha Clinics to expand and accommodate a broad array of stem
cell-based clinical trials, where the trial meets the scientific,
clinical trial design and ethical standards set forth by the Alpha
Clinics Network, as well as FDA approved treatments.”The coordinating and information center
would be expected to :
“Build relationships with
Accountable Care Organizations, and participate in initiatives for
informing coverage and payment decisions
“Design strategies to attract
investors and philanthropists to CASC network
“Create business plans, and marketing
and branding strategies for financial sustainability of the Alpha
Clinics Sites and (the coordination/information center)”.
Source:Stem Cell Therapy
Comments Off on California’s $70 Million ‘Alpha’ Stem Cell Clinic Plan Headed for Approval Next Week |
July 21st, 2013
Emilie Russler and David Germain – New York Times
By Dr. Matthew Watson
Emilie Russler and David Germain New York Times Next month, the bride, who is studying for a Ph.D. in immunology, is to begin her second year and the groom, studying for a doctorate in molecular genetics and genomics, his fifth. The bride's mother retired as the director and the deputy to the ... |
Uncategorized
Comments Off on Emilie Russler and David Germain – New York Times |
July 21st, 2013
Indian Hill Music School donating sets and props for Newtown production – Boston Globe
By Dr. Matthew Watson
 Boston Globe | Indian Hill Music School donating sets and props for Newtown production Boston Globe Wayland resident Lindsay Farrer (inset bottom) is a medical geneticist at the Boston University Schools of Medicine and Public Health, where he is a professor, chief of biomedical genetics, and director of the Molecular Genetics Core Facility. He ... |
Uncategorized
Comments Off on Indian Hill Music School donating sets and props for Newtown production – Boston Globe |
July 21st, 2013
Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3?CTV)
By Dr. Matthew Watson
Abstract
Few options are available for treating patients with advanced prostate cancer (PC). As PC is a slow growing disease and accessible by ultrasound, gene therapy could provide a viable option for this neoplasm. Conditionally replication?competent adenoviruses (CRCAs) represent potentially useful reagents for treating prostate cancer (PC). We previously constructed a CRCA, Cancer Terminator Virus (CTV), which showed efficacy both in vitro and in vivo for PC. The CTV was generated on a serotype 5?background (Ad.5?CTV) with infectivity depending on Coxsackie?Adenovirus Receptors (CARs). CARs are frequently reduced in many tumor types, including PCs thereby limiting effective Ad?mediated therapy. Using serotype chimerism, a novel CTV (Ad.5/3?CTV) was created by replacing the ...
MedWorm Sponsor Message: Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
Uncategorized
Comments Off on Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3?CTV) |
July 20th, 2013
Avascular necrosis treatment with bone marrow stem cells. – Video
By Dr. Matthew Watson
Avascular necrosis treatment with bone marrow stem cells.
Avascular necrosis treatment with stem cells from bone marrow. Visit http://www.blog.hipsurgery.in to get details of types of treatment. Visit http://www.hipsurgery...
By: ALAMPALLAM VENKATACHALAM
Excerpt from:
Avascular necrosis treatment with bone marrow stem cells. - Video
Bone Marrow Stem Cells
Comments Off on Avascular necrosis treatment with bone marrow stem cells. – Video |
July 18th, 2013
Stem Cell Therapy Treatment for Idiopathic Polymyositis by Dr Alok Sharma, Mumbai, India. – Video
By Dr. Matthew Watson
Stem Cell Therapy Treatment for Idiopathic Polymyositis by Dr Alok Sharma, Mumbai, India.
Improvement seen in just 5 day after Stem Cell Therapy Treatment for Idiopathic Polymyositis by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Fle...
By: Neurogen Brain and Spine Institute
More here:
Stem Cell Therapy Treatment for Idiopathic Polymyositis by Dr Alok Sharma, Mumbai, India. - Video
Uncategorized
Comments Off on Stem Cell Therapy Treatment for Idiopathic Polymyositis by Dr Alok Sharma, Mumbai, India. – Video |
July 17th, 2013
Genetic Engineering, Biotechnology and the Future Of Humanity – Center for Research on Globalization
By Dr. Matthew Watson
 The Express Tribune | Genetic Engineering, Biotechnology and the Future Of Humanity Center for Research on Globalization In the UK, Genewatch UK has revealed how Monsanto, Syngenta, Bayer, and BASF (all biotech companies) under the guise of the 'Agricultural Biotechnology Council' held a meeting in June 2012 with government ministers and academics to formulate a ... Agricultural sector promotes biotechnologyThe Express Tribune Food Minister for using biotechnology to reduce food insecurityPakistanToday.com.pk |
Uncategorized
Comments Off on Genetic Engineering, Biotechnology and the Future Of Humanity – Center for Research on Globalization |
July 14th, 2013
ThyssenKrupp inaugurated biotechnology in Leuna – SteelGuru
By Dr. Matthew Watson
ThyssenKrupp inaugurated biotechnology in Leuna SteelGuru Dr. Heinrich Hiesinger CEO of ThyssenKrupp said that “Modern biotechnology is one of the key technologies of the 21st century. Biotechnological processes, products and services play a role in almost all areas of our daily lives for example in the ... |
Uncategorized
Comments Off on ThyssenKrupp inaugurated biotechnology in Leuna – SteelGuru |
July 14th, 2013
Is Alynlam the next breakthrough name in biotechnology? Investors say ‘yes’ – MedCity News
By Dr. Matthew Watson
 Boston Globe | Is Alynlam the next breakthrough name in biotechnology? Investors say 'yes' MedCity News (Reuters) - A radical new treatment for genetic disorders has catapulted Alnylam Pharmaceuticals Inc into the crosshairs of investors seeking the next breakthrough name in biotechnology. The challenge for the Cambridge, Massachusetts-based company ... Stocks to Keep Your Eyes on - Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN ...Techsonian Alnylam Pharmaceuticals (ALNY) Shares Soar After Positive Drug Trial ResultsNew Stuff Here Alnylam Reports Positive Top-Line Results for ALN-TTRsc, a Subcutaneously ...EON: Enhanced Online News (press release) |
Uncategorized
Comments Off on Is Alynlam the next breakthrough name in biotechnology? Investors say ‘yes’ – MedCity News |
July 14th, 2013
Wisconsin Alumni Research Foundation ranks fourth in biotechnology patents – 77Square.com
By Dr. Matthew Watson
Wisconsin Alumni Research Foundation ranks fourth in biotechnology patents 77Square.com Bioentrepreneur, a website affiliated with the journal Nature, has ranked UW-Madison's Wisconsin Alumni Research Foundation (WARF) the fourth-most-active entity in biotechnology patents issued in the U.S. and Europe from 2008 to 2012. In that span ... |
Uncategorized
Comments Off on Wisconsin Alumni Research Foundation ranks fourth in biotechnology patents – 77Square.com |
July 14th, 2013
First microRNA mimic enters clinic – Nature.com
By Dr. Matthew Watson
First microRNA mimic enters clinic Nature.com Nature Biotechnology. Full text access provided to Google by Bot. Cart. Search Go Advanced search · nature.com · journal home · current issue · News; full text. Nature Biotechnology | News. Print; Email; Share/bookmark. Cite U Like · Facebook · Twitter ... |
Uncategorized
Comments Off on First microRNA mimic enters clinic – Nature.com |
July 14th, 2013
Is There A Sickle Cell Cure? – Lasentinel
By Dr. Matthew Watson
Is There A Sickle Cell Cure? Lasentinel “We're publishing a paper describing some pre-clinical studies that we've been doing over the last three years,” said Dr. Donald Kohn, M.D. professor at UCLA, department of microbiology, immunology, and molecular genetics, the department of pediatrics ... |
Uncategorized
Comments Off on Is There A Sickle Cell Cure? – Lasentinel |
July 14th, 2013